1865-P: Advancing Diabetes by Simplifying Insulin Delivery

Introduction and Objective: Treatment engagement in individuals with diabetes who are using MDI therapy remains burdensome. On average 72% of patients have reported not taking insulin outside of their home. Insulin patch devices can reduce the burden and complexity of MDI therapy and improve glycemic outcomes. We investigated the impact of treatment with the CeQur Simplicity™ patch device on glycemic management and user perceptions in a large cohort of adults previously treated with MDI therapy. Methods: This was a single-arm, real-world, observational study. No changes in insulin dose or therapeutic management were performed by investigators during the 60-90 days of onboarding. The primary outcome measures were changes in self-reported glycemic metrics (e.g., A1C/GMI, %TIR). Results: A total of 1,073 adults with diabetes were enrolled; 876 participants with insulin-treated diabetes, mean age 59.2±14.7 years, had self-reported pre- and post-initiation A1C or GMI and 555 had pre- and post-initiation %TIR. Significant reductions in A1C/GMI and increases in %TIR were observed at 60-90 days follow-up. (Figure 1) At pre-initiation only 20.9% (116/555)of patients had %TIR ≥70%, which increased to 41.6% (213/555) post-initiation. The 12.4% increase in %TIR equates to ~3 hours of their day. Conclusion: Treatment with the CeQur Simplicity bolus insulin patch is associated with significant improvements in user-reported glycemic management with no other interventions. Disclosure A. Carlson: Research Support; Current; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company. Other - Research support and consulting/speaking; Current; Insulet Corporation. Research Support; Current; Lexicon Pharmaceuticals, Inc. Advisory Panel; Current; MannKind Corporation. Other - Research support and advisory panel; Current; Medtronic, Novo Nordisk A/S, Zealand Pharma A/S. Advisory Panel; Current; Tandem Diabetes Care, Inc. J. Duffee: Employee; Current; CeQur SA. Employee; Ended; OrganOx. L. Morini: None. J. Allaire: None. C.G. Parkin: Consultant; Current; Abbott Diabetes, CeQur SA, Dexcom, Inc., Tandem Diabetes Care, Inc., MannKind Corporation, Roche Diagnostics. C. Carter: Employee; Current; CeQur SA.